| Literature DB >> 29345578 |
Nicola Sgaramella1,2,3, Xiaolian Gu1, Linda Boldrup1, Philip J Coates4, Robin Fahraeus1,4,5, Luigi Califano3, Gianpaolo Tartaro2, Giuseppe Colella2, Lena Norberg Spaak6, Adrian Strom6, Torben Wilms6, Lorenzo Lo Muzio7, Giovanni Dell'Aversana Orabona3, Mario Santagata2, Lotta Loljung1, Riccardo Rossiello8, Karin Danielsson9, Klas Strindlund1, Sandra Lillqvist1, Karin Nylander1.
Abstract
Squamous cell carcinoma of the head and neck, SCCHN, is a heterogeneous group of tumours not only concerning the site of origin but also regarding aetiology. The 5-year survival for the whole group of SCCHN tumours has not significantly improved over the last 20-25 years. Apart from tumour spread to lymph nodes, N status, gains and losses of specific chromosomes are the only factors shown to be independent prognostic markers for these tumours. Worldwide, an increasing number of people ≤ 40 years are seen being affected by tongue SCC, the most common tumour within the SCCHN group. Even without any clinical signs of metastasis, up to 30% of all tongue SCC have histologically detectable spread to lymph nodes. In this mini review, field cancerization, tumour microenvironment, the so called EMT (epithelial mesenchymal transition) process and the role of viruses in development of SCCHN are discussed as well as potential new therapeutic targets. For the group of tongue SCC, with the increasing incidence seen in young patients and particularly women, new data with impact on prognosis and treatment are urgently needed. But as long as data from the analyses of several sub sites are presented as valid for the whole group of tumours, this vital point is missed. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.Entities:
Keywords: EBV; HPV; Prognosis; Squamous cell carcinoma; Therapy; Tongue; miRNA; p63.
Mesh:
Substances:
Year: 2018 PMID: 29345578 DOI: 10.2174/1568026618666180116121624
Source DB: PubMed Journal: Curr Top Med Chem ISSN: 1568-0266 Impact factor: 3.295